Urethral cancer
Drug research and approvals for urethral cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 24 studies of urethral cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 24
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Photon-Counting Computed Tomography-Based Urethral Visualization Without Catheterization for Radiotherapy Planning: A…NCT07730203 · Not reported · Istituto Clinico Humanitas · starts Jun 22, 2026
- Intraoperative Neuromonitoring of Sacral Reflexes to Predict Post Operative Function in Patients Undergoing Sacrectomy…NCT07707024 · Not applicable · City of Hope Medical Center · starts Jan 10, 2027
- MRI-DTI Assessment of Urethral Internal Sphincter Ring and Prostate Base MorphologyNCT07694752 · Not reported · Jiangsu Taizhou People's Hospital · starts Jul 15, 2026
- Total en Bloc Urethra Preservation at Robot-assisted Prostatectomy IDEAL Stage 2aNCT07678489 · Not applicable · Sami-Ramzi Leyh-Bannurah · starts Jan 30, 2024
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced…NCT07217171 · Phase 1 · EvolveImmune United, Inc · starts Nov 13, 2025
- DESTINY-PANTUMOUR04NCT07124000 · Not reported · AstraZeneca · starts Sep 18, 2025
- Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial CarcinomaNCT06983210 · Phase 2 · Nagoya University · starts May 1, 2025
- A Technique Improves Urinary Continence in Patients Undergoing Laparoscopic Radical ProstatectomyNCT06754488 · Not applicable · Suzhou Municipal Hospital · starts Jan 1, 2025
- Retzius-sparing Robot-assisted Radical Prostatectomy With "Sandwich" Technique of Total Urethral Reconstruction Versus…NCT06730243 · Not applicable · Ministry of Science and Technology of the People´s Republic of China · starts Jan 1, 2023
Phase 3 7
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
- CisplatinDNA inhibitor
- CarboplatinDNA inhibitor
- PaclitaxelTubulin inhibitor
- DoxorubicinDNA topoisomerase II alpha inhibitor
- MethotrexateDihydrofolate reductase inhibitor
- VinblastineTubulin inhibitor
Phase 2 12 of 22
- SunitinibMacrophage colony stimulating factor receptor inhibitor
- PazopanibMacrophage colony stimulating factor receptor inhibitor
- TrastuzumabReceptor protein-tyrosine kinase erbB-2 inhibitor
- FluorouracilThymidylate synthase inhibitor
- Bortezomib26S proteasome inhibitor
- Arsenic trioxideThioredoxin reductase 1 inhibitor
- DocetaxelTubulin inhibitor
- IfosfamideDNA inhibitor
- IrinotecanDNA topoisomerase I inhibitor
- IxabepiloneTubulin inhibitor
- VandetanibTyrosine-protein kinase SRC inhibitor
- AfliberceptVascular endothelial growth factor A inhibitor
Phase 1 or earlier 4
- LenalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- TemsirolimusFK506-binding protein 1A inhibitor
- Edodekin alfa
- Pemvidutide
How its trials ended
79 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 21 whose ending is known, 29% met their primary endpoint, 33% missed it and 38% stopped early.
- Completed, result not reported3646%
- Ongoing1924%
- Missed its primary endpoint79%
- Met its primary endpoint68%
- Stopped: enrollment or feasibility45%
- Stopped: other or unclear34%
- Status unknown34%
- Stopped: safety11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA